US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
US4908056A
(en)
|
1986-04-25 |
1990-03-13 |
E. I. Du Pont De Nemours And Company |
Heterocyclic acyl sulfonamides
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
EP0352575A3
(de)
|
1988-07-28 |
1991-08-21 |
Bayer Ag |
Substituierte anellierte Pyrrole
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
CA2122732C
(en)
|
1991-11-25 |
2008-04-08 |
Marc D. Whitlow |
Multivalent antigen-binding proteins
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
IT1269176B
(it)
|
1994-01-11 |
1997-03-21 |
Isagro Srl |
Eterobicicli ad attivita' fungicida
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
ATE219517T1
(de)
|
1995-08-18 |
2002-07-15 |
Morphosys Ag |
Protein-/(poly)peptidbibliotheken
|
EP1047761A1
(en)
|
1997-10-14 |
2000-11-02 |
The Procter & Gamble Company |
Hard surface cleaning compositions comprising mid-chain branched surfactants
|
US6982265B1
(en)
|
1999-05-21 |
2006-01-03 |
Bristol Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
AU7491400A
(en)
*
|
1999-09-17 |
2001-04-17 |
Abbott Gmbh & Co. Kg |
Kinase inhibitors as therapeutic agents
|
ID30204A
(id)
|
1999-12-27 |
2001-11-15 |
Japan Tobacco Inc |
Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
|
US6770666B2
(en)
|
1999-12-27 |
2004-08-03 |
Japan Tobacco Inc. |
Fused-ring compounds and use thereof as drugs
|
SI1294358T1
(sl)
|
2000-06-28 |
2004-12-31 |
Smithkline Beecham Plc |
Mokro mletje
|
HUP0304093A3
(en)
|
2001-04-06 |
2008-08-28 |
Wyeth Corp |
Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
|
AR035543A1
(es)
|
2001-06-26 |
2004-06-16 |
Japan Tobacco Inc |
Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
|
WO2004035580A1
(en)
|
2002-10-21 |
2004-04-29 |
Aprea Ab |
Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1585767A2
(en)
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
WO2004082606A2
(en)
|
2003-03-13 |
2004-09-30 |
Synta Pharmaceuticals Corp. |
Fused pyrrole compounds
|
EP1608628A2
(en)
|
2003-03-17 |
2005-12-28 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
DK1639014T3
(da)
|
2003-06-13 |
2011-01-17 |
Biogen Idec Inc |
Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
|
FR2857966A1
(fr)
|
2003-07-24 |
2005-01-28 |
Aventis Pharma Sa |
Produits aryl-heteroaromatiques, compositions les contenant et utilisation
|
CA2536408A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
WO2005025515A2
(en)
|
2003-09-12 |
2005-03-24 |
California Institute Of Technology |
Proteasome pathway inhibitors and related methods
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
UY28931A1
(es)
*
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
MY139689A
(en)
*
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US20070015771A1
(en)
|
2004-07-29 |
2007-01-18 |
Threshold Pharmaceuticals, Inc. |
Lonidamine analogs
|
US20070043057A1
(en)
|
2005-02-09 |
2007-02-22 |
Threshold Pharmaceuticals, Inc. |
Lonidamine analogs
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
CA2586605A1
(en)
|
2004-11-24 |
2006-06-01 |
Novartis Ag |
Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
|
WO2006124874A2
(en)
|
2005-05-12 |
2006-11-23 |
Kalypsys, Inc. |
Inhibitors of b-raf kinase
|
ES2401099T3
(es)
|
2005-11-02 |
2013-04-16 |
Bayer Intellectual Property Gmbh |
Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
|
PL2385053T3
(pl)
|
2005-11-17 |
2014-05-30 |
Osi Pharmaceuticals Llc |
Związki pośrednie do wytwarzania skondensowanych bicyklicznych inhibitorów mTOR
|
US7514435B2
(en)
|
2005-11-18 |
2009-04-07 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
CN101448506A
(zh)
|
2005-12-02 |
2009-06-03 |
拜尔健康护理有限责任公司 |
通过抑制有丝***酶激酶治疗癌症的吡咯并三嗪衍生物
|
WO2007064931A2
(en)
|
2005-12-02 |
2007-06-07 |
Bayer Healthcare Llc |
Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
ES2700433T3
(es)
|
2005-12-13 |
2019-02-15 |
Incyte Holdings Corp |
Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus
|
CA2633035C
(en)
|
2005-12-15 |
2016-05-10 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and their uses
|
EP1973917B1
(en)
|
2005-12-29 |
2015-06-10 |
AbbVie Inc. |
Protein kinase inhibitors
|
JP5313875B2
(ja)
|
2006-04-12 |
2013-10-09 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
増殖性疾患の処置のためのタンパク質キナーゼplk1の阻害剤として有用な4,5−ジヒドロ−[1,2,4]トリアゾロ[4,3−f]プテリジン
|
KR101464385B1
(ko)
|
2006-04-19 |
2014-11-21 |
노파르티스 아게 |
6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
|
US20090253718A1
(en)
|
2006-04-25 |
2009-10-08 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
US8022088B2
(en)
|
2006-06-29 |
2011-09-20 |
Schering Corporation |
Substituted bicyclic and tricyclic thrombin receptor antagonists
|
WO2008012635A2
(en)
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
US8097630B2
(en)
|
2006-10-10 |
2012-01-17 |
Rigel Pharmaceuticals, Inc. |
Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
|
WO2008064157A1
(en)
*
|
2006-11-22 |
2008-05-29 |
Incyte Corporation |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
EP2099430A2
(en)
|
2006-12-07 |
2009-09-16 |
Schering Corporation |
Ph sensitive matrix formulation
|
MX2009006345A
(es)
|
2006-12-14 |
2009-06-23 |
Vertex Pharma |
Compuestos utiles como inhibidores de proteina cinasa.
|
US9650391B2
(en)
|
2006-12-29 |
2017-05-16 |
Rigel Pharmaceuticals Inc. |
N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
|
WO2008083353A1
(en)
|
2006-12-29 |
2008-07-10 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
RS53281B
(en)
|
2006-12-29 |
2014-08-29 |
Rigel Pharmaceuticals Inc. |
POLYCYCLIC HETEROaryl SUBSTITUTED TRIAZOLES USED AS AXL INHIBITORS
|
CA2674589A1
(en)
|
2007-01-12 |
2008-07-24 |
Biocryst Pharmaceuticals, Inc. |
Antiviral nucleoside analogs
|
EP2114983B8
(en)
|
2007-02-07 |
2015-02-18 |
The Regents of the University of Colorado, A Body Corporate |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
US8124759B2
(en)
|
2007-05-09 |
2012-02-28 |
Abbott Laboratories |
Inhibitors of protein kinases
|
ES2393038T3
(es)
|
2007-05-10 |
2012-12-18 |
Biocryst Pharmaceuticals, Inc. |
Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
|
JP2010532756A
(ja)
|
2007-07-06 |
2010-10-14 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
mTORC1及びmTORC2の両方の阻害剤を含む組み合わせ抗癌療法
|
WO2009009016A1
(en)
|
2007-07-06 |
2009-01-15 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
MX2010001677A
(es)
|
2007-08-15 |
2010-03-11 |
Vertex Pharma |
Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
|
AU2008304620A1
(en)
|
2007-09-25 |
2009-04-02 |
Bayer Healthcare Llc |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
CA2703653A1
(en)
|
2007-10-25 |
2009-04-30 |
Astrazeneca Ab |
Pyridine and pyrazine derivatives -083
|
CA2704052C
(en)
|
2007-10-26 |
2015-04-21 |
Rigel Pharmaceuticals, Inc. |
Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
DE102007051762A1
(de)
|
2007-10-30 |
2009-05-07 |
Bayer Healthcare Ag |
Substituierte Pyrrolotriazine und ihre Verwendung
|
AU2008343932B2
(en)
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
KR20110017845A
(ko)
|
2008-03-19 |
2011-02-22 |
오에스아이 파마슈티컬스, 인코포레이티드 |
Mtor 억제자 염 형태
|
MX2010011224A
(es)
|
2008-04-16 |
2011-02-25 |
Max Planck Ges Zur Fa Rderung Der Wissenschaften E V |
Derivados de quinoleina como inhibidores de la cinasa axl.
|
CN104262345B
(zh)
|
2008-04-23 |
2017-06-23 |
吉利德科学公司 |
用于抗病毒治疗的1’‑取代的carba‑核苷类似物
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
KR20110018376A
(ko)
|
2008-06-23 |
2011-02-23 |
스미또모 가가꾸 가부시키가이샤 |
조성물 및 상기 조성물을 이용하여 이루어지는 발광 소자
|
MX2011000026A
(es)
|
2008-06-23 |
2011-02-24 |
Vertex Pharma |
Inhibidores de proteina cinasas.
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
ES2399319T3
(es)
|
2008-07-09 |
2013-03-27 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con heteroarilos bicíclicos que contienen puentes útiles como inhibidores de AXL
|
ES2537480T3
(es)
|
2008-07-09 |
2015-06-08 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
|
US20120230991A1
(en)
|
2008-07-29 |
2012-09-13 |
Douglas Kim Graham |
Methods and compounds for enhancing anti-cancer therapy
|
WO2010025073A1
(en)
|
2008-08-28 |
2010-03-04 |
Takeda Pharmaceutical Company Limited |
Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
|
WO2010048123A2
(en)
|
2008-10-20 |
2010-04-29 |
Eckhardt S Gail |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
WO2010071885A1
(en)
|
2008-12-19 |
2010-06-24 |
Cephalon, Inc. |
Pyrrolotriazines as alk and jak2 inhibitors
|
CN102307875A
(zh)
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
US20100204265A1
(en)
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
KR20100101054A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
WO2010135650A1
(en)
|
2009-05-22 |
2010-11-25 |
Incyte Corporation |
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
|
US8940752B2
(en)
|
2009-06-29 |
2015-01-27 |
Incyte Corporation |
Pyrimidinones as PI3K inhibitors
|
US20120128670A1
(en)
|
2009-07-31 |
2012-05-24 |
OSI Pharmaceuticals, LLC |
mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
SI2480559T1
(sl)
|
2009-09-21 |
2013-10-30 |
Gilead Sciences, Inc. |
Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
|
DK2480552T3
(en)
|
2009-09-21 |
2017-02-20 |
Gilead Sciences Inc |
2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
|
WO2011038185A2
(en)
|
2009-09-25 |
2011-03-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
EP3070077B1
(en)
|
2009-10-06 |
2018-11-28 |
Millennium Pharmaceuticals, Inc. |
Heterocyclic compounds useful as pdk1 inhibitors
|
EP2311809A1
(en)
|
2009-10-16 |
2011-04-20 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinolinyloxyphenylsulfonamides
|
US8604217B2
(en)
|
2009-11-12 |
2013-12-10 |
Selvita S.A. |
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
|
US8680108B2
(en)
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
CA2787714C
(en)
|
2010-01-22 |
2019-04-09 |
Joaquin Pastor Fernandez |
Inhibitors of pi3 kinase
|
ES2662588T3
(es)
|
2010-03-10 |
2018-04-09 |
Incyte Holdings Corporation |
Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
|
WO2011123493A1
(en)
*
|
2010-03-31 |
2011-10-06 |
Bristol-Myers Squibb Company |
Substituted pyrrolotriazines as protein kinase inhibitors
|
CA2761074A1
(en)
|
2010-05-05 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
|
WO2011141713A1
(en)
|
2010-05-13 |
2011-11-17 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
New bicyclic compounds as pi3-k and mtor inhibitors
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
GB2480814A
(en)
|
2010-06-01 |
2011-12-07 |
Summit Corp Plc |
Compounds for the treatment of clostridium difficile-associated disease
|
KR102108864B1
(ko)
|
2010-07-19 |
2020-05-12 |
길리애드 사이언시즈, 인코포레이티드 |
부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
EP2423208A1
(en)
|
2010-08-28 |
2012-02-29 |
Lead Discovery Center GmbH |
Pharmaceutically active compounds as Axl inhibitors
|
US20120077814A1
(en)
|
2010-09-10 |
2012-03-29 |
Zhong Wang |
Sulfonamide, sulfamate, and sulfamothioate derivatives
|
TW201305185A
(zh)
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
用於抗病毒治療之2’-氟取代之碳-核苷類似物
|
CA2811773A1
(en)
|
2010-09-29 |
2012-04-05 |
Kissei Pharmaceutical Co., Ltd. |
(aza)indolizine derivative and pharmaceutical use thereof
|
US20120115848A1
(en)
|
2010-10-08 |
2012-05-10 |
Elan Pharmaceuticals, Inc. |
Inhibitors of Polo-Like Kinase
|
CN103249732B
(zh)
|
2010-10-08 |
2016-08-10 |
生物区欧洲有限公司 |
抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii
|
ITRM20100537A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
MX352844B
(es)
|
2011-02-28 |
2017-12-11 |
Calitor Sciences Llc |
Compuestos de quinolina sustituidos y metodos de uso.
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
HUE046988T2
(hu)
|
2011-04-01 |
2020-04-28 |
Univ Utah Res Found |
Szubsztituált N-fenilpirimidin-2-amin analógok mint AXL kináz inhibitorok
|
CA2836769C
(en)
|
2011-05-04 |
2018-11-13 |
Intellikine, Llc |
The combination of paclitaxel and an mtor inhibitor for the treatment of a proliferative disorder
|
WO2012154608A1
(en)
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
EA025496B1
(ru)
|
2011-05-17 |
2016-12-30 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
DK2710007T3
(da)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
KR20140036269A
(ko)
|
2011-07-01 |
2014-03-25 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
CA2846652C
(en)
|
2011-09-02 |
2019-11-05 |
Incyte Corporation |
Heterocyclylamines as pi3k inhibitors
|
EP2758052B9
(en)
|
2011-09-18 |
2019-03-27 |
Euro-Celtique S.A. |
Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
US9273056B2
(en)
|
2011-10-03 |
2016-03-01 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
CN106994126A
(zh)
|
2011-11-08 |
2017-08-01 |
因特利凯有限责任公司 |
使用多种药剂的治疗方案
|
CN108047201A
(zh)
|
2011-11-14 |
2018-05-18 |
亚尼塔公司 |
作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
|
CN104363914A
(zh)
|
2011-11-23 |
2015-02-18 |
因特利凯有限责任公司 |
使用mTOR抑制剂的增强的治疗方案
|
WO2013085802A1
(en)
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
UY34484A
(es)
|
2011-12-15 |
2013-07-31 |
Bayer Ip Gmbh |
Benzotienilo-pirrolotriazinas disustituidas y sus usos
|
US9598416B2
(en)
|
2011-12-15 |
2017-03-21 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
|
EP2809673B1
(en)
|
2012-01-31 |
2016-11-02 |
Nanjing Allgen Pharma Co. Ltd. |
Spirocyclic molecules as bruton's tyrosine kinase inhibitors
|
KR102078530B1
(ko)
|
2012-01-31 |
2020-02-18 |
다이이찌 산쿄 가부시키가이샤 |
피리돈 유도체들
|
WO2013124316A1
(en)
|
2012-02-23 |
2013-08-29 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
US20150057243A1
(en)
|
2012-04-02 |
2015-02-26 |
Northern University |
Compositions and Methods for the Inhibition of Methyltransferases
|
CN103373996A
(zh)
|
2012-04-20 |
2013-10-30 |
山东亨利医药科技有限责任公司 |
作为crth2受体拮抗剂的二并环衍生物
|
WO2013162061A1
(ja)
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
DK2861599T3
(da)
|
2012-06-18 |
2020-03-02 |
Principia Biopharma Inc |
Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
|
CN104583210B
(zh)
|
2012-06-19 |
2018-06-01 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
BR112014030147B1
(pt)
|
2012-06-22 |
2019-10-15 |
Sumitomo Chemical Company, Limited |
Compostos heterocíclicos fundidos, composição e método para controlar pestes
|
US9572811B2
(en)
|
2012-08-03 |
2017-02-21 |
Principia Biopharma Inc. |
Treatment of dry eye
|
WO2014035140A2
(en)
|
2012-08-30 |
2014-03-06 |
Kainos Medicine, Inc. |
Compounds and compositions for modulating histone methyltransferase activity
|
AU2013312477B2
(en)
|
2012-09-06 |
2018-05-31 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2014042433A2
(en)
|
2012-09-14 |
2014-03-20 |
Kainos Medicine, Inc. |
Compounds and compositions for modulating adenosine a3 receptor activity
|
CN104995192A
(zh)
|
2012-09-26 |
2015-10-21 |
加利福尼亚大学董事会 |
Ire1的调节
|
WO2014059901A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
US9562047B2
(en)
|
2012-10-17 |
2017-02-07 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
WO2014059902A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
WO2014071031A1
(en)
|
2012-11-01 |
2014-05-08 |
Incyte Corporation |
Tricyclic fused thiophene derivatives as jak inhibitors
|
AU2013344422A1
(en)
|
2012-11-16 |
2015-07-02 |
Biocryst Pharmaceuticals, Inc. |
Antiviral azasugar-containing nucleosides
|
EP2922857B1
(en)
|
2012-11-20 |
2018-01-03 |
ProQinase GmbH |
Thioether derivatives as protein kinase inhibitors
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
CN105073741B
(zh)
|
2013-01-18 |
2017-08-08 |
百时美施贵宝公司 |
作为rock抑制剂的酞嗪酮及异喹啉酮
|
WO2014113942A1
(en)
|
2013-01-23 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
US20140357636A1
(en)
|
2013-02-21 |
2014-12-04 |
Wayne Rothbaum |
Treatment of Skeletal-Related Disorders
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
US9012466B2
(en)
|
2013-03-12 |
2015-04-21 |
Arqule Inc. |
Substituted tricyclic pyrazolo-pyrimidine compounds
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
WO2015058084A1
(en)
|
2013-10-18 |
2015-04-23 |
Medivation Technologies, Inc. |
Heterocyclic compounds and methods of use
|
WO2015066371A1
(en)
|
2013-10-31 |
2015-05-07 |
Forum Pharmaceuticals, Inc. |
SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
|
JP6493218B2
(ja)
|
2013-11-08 |
2019-04-03 |
小野薬品工業株式会社 |
ピロロピリミジン誘導体
|
CA2934989C
(en)
*
|
2014-02-03 |
2017-08-08 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
EP3104712B1
(en)
|
2014-02-12 |
2020-05-06 |
Firmenich Incorporated |
Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
WO2016183071A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Hetero-tricyclic compounds and their use for the treatment of cancer
|
WO2017027717A1
(en)
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Bicyclic fused pyrimidine compounds as tam inhibitors
|
WO2017035366A1
(en)
|
2015-08-26 |
2017-03-02 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as tam inhibitors
|
US20180296561A1
(en)
|
2015-10-07 |
2018-10-18 |
The University Of North Carolina At Chapel Hill |
The Methods For Treatment Of Tumors
|
CO2018003968A2
(es)
|
2015-10-13 |
2018-09-20 |
Nihon Nohyaku Co Ltd |
Compuesto heterocíclico condensado con contenido de grupo oxima o su sal, insecticida agrícola y hortícola que comprende el compuesto y método para controlar plagas.
|
US9920033B2
(en)
|
2015-11-14 |
2018-03-20 |
Calitor Sciences, Llc |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
JP6905662B2
(ja)
|
2015-11-14 |
2021-07-21 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
置換キノリン化合物の結晶形およびその医薬組成物
|
RS65129B1
(sr)
*
|
2016-03-28 |
2024-02-29 |
Incyte Corp |
Jedinjenja pirolotriazina kao inhibitori tam
|
WO2017184934A1
(en)
|
2016-04-22 |
2017-10-26 |
Incyte Corporation |
Formulations of an lsd1 inhibitor
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
IL264216B2
(en)
|
2016-07-15 |
2024-04-01 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating SMN2
|
JOP20170153A1
(ar)
|
2016-07-15 |
2019-01-30 |
Lilly Co Eli |
نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
|
WO2019067594A1
(en)
|
2017-09-27 |
2019-04-04 |
Incyte Corporation |
SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS
|
PE20211805A1
(es)
|
2018-06-29 |
2021-09-14 |
Incyte Corp |
Formulaciones de un inhibidor de axl/mer
|
US20210275666A1
(en)
|
2020-03-06 |
2021-09-09 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|